Pharma sales continue to rise for Boehringer Ingelheim
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's 2009 prescription pharmaceutical sales rose by 10% to more than €10 billion. The core products Spiriva (tiotropium bromide), Alna/Flomax (tamsulosin HCl), Micardis (telmisartan) and Sifrol/Mirapex (pramipexole) drove growth and achieved aggregate sales of €6 billion.